

1 PRODUCT NAME

Glycoprep-C® powder 70 g sachet

Glycoprep-C® powder 210 g sachet

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The active ingredients are:

- macrogol 3350 has a chemical formula of HOCH₂ [CH₂OCH₂]_m. CH₂OH (where 'm' equals 45 to 70).
- sodium chloride has a chemical formula of NaCl, a MW of 58.44 and a CAS No. 7647-14-5.
- potassium chloride has a chemical formula of KCl, a MW of 74.6 and a CAS No. 7447-40-7.
- sodium sulfate has a chemical formula of Na₂SO₄, a MW of 142.0 and a CAS No. 7757-82-6.

Each 70 g or 210 g sachet contains macrogol 3350 (polyethylene glycol) 755.69 mg/g, sodium sulfate (anhydrous) 80.62 mg/g, sodium chloride 37.33 mg/g, potassium chloride 10.55 mg/g, citric acid 12.77 mg/g, ascorbic acid 85.16 mg/g, aspartame 5.11 mg/g and lemon flavour 12.77 mg/g.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

Powder for solution.

Glycoprep-C® powder for solution is a white crystalline powder packed in a sachet containing 70 g or 210 g. When dissolved in water it produces a solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Glycoprep-C® is indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal procedure (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (IVP) or colonic surgery.

4.2 Dose and method of administration

For Oral Use.

Glycoprep-C® is usually taken the day before the procedure. This may be varied if considered appropriate by the doctor.

Guidance for clinicians/doctors: Glycoprep-C® can be taken in the evening prior to the procedure (if a morning procedure) or on the morning of the procedure (if an afternoon procedure).

On the day before the procedure

Patients should fast until after the procedure. Patients should only drink recommended clear sugar free fluids. During the day, patients should drink at least one glass (approx. 250 mL) of fluids each hour to maintain hydration. Solid foods or milk products should not be taken.

** Recommended clear sugar free fluids: water, soups (e.g. strained chicken noodle soup), broth/bouillon, fruit juices (apple, pear, white grape), black tea or coffee (no milk), electrolyte

NEW ZEALAND DATA SHEET

replacing drinks, cordials (lemon / lime), plain jelly (no red or purple colourings). Barley sugar may be sucked if required.

The patient should not drink carbonated or alcoholic beverages.

Glycoprep-C[®] produces a watery diarrhoea which empties and cleanses the bowel before procedure or surgery. It should be prepared and taken according to the directions. The onset of diarrhoea is about 1 hour and should be complete in 4 hours.

Preparation of Solution

The contents of the 70 g sachet should be dissolved in 1 litre of water using a suitable food grade container; or, the contents of the 210 g sachet should be dissolved in 3 litres of water using a suitable food grade container. The solution may be chilled if desired.

Usual Dosage

Glycoprep-C[®] is usually taken orally but may be given by nasogastric tube to patients who are unwilling or unable to drink it.

A total of 210 g of Glycoprep-C[®] will be required for the procedure. Three lots of 70 g sachets can be prepared and used as required or one 210 g sachet can be prepared at once and used instead.

The patient should fast for 2 hours before starting to take Glycoprep-C[®] and only take clear fluids until after the procedure.

One or two 250 mL glasses of the prepared solution should be taken every 15-20 minutes. The recommended dosing intake rate is from 1.2 litres to 1.8 litres per hour. If nausea is experienced, the rate of intake of Glycoprep-C[®] solution should be reduced. Lavage is complete when the faecal discharge is clear.

No food should be taken for 2 hours prior to commencing dosing. Only clear fluids are allowed during the interval between commencing the Glycoprep-C[®] preparation and 6 hours prior to the procedure.

For Nasogastric Intubation

Infuse the prepared solution at a rate of 20 to 30 mL/minute.

It is important that the patient follow the recommended dosing schedule.

Note: Individual responses to laxatives may vary. The preparation may cause multiple bowel movements and usually induces frequent loose bowel movements within 2 to 3 hours of taking the first dose. Patients should be advised to remain within easy reach of toilet facilities and not plan to go out.

4.3 Contraindications

Glycoprep-C[®] should not be used by patients with hypersensitivity to any of the ingredients, phenylketonuria, gastrointestinal obstruction, gastric retention, bowel perforation (frank or suspected), toxic colitis, toxic megacolon, ileus, severe dehydration or whose body weight is less than 20 kg.

4.4 Special warnings and precautions for use

Use with caution in patients with severe ulcerative colitis, those with a stoma, impaired renal function, pre-existing electrolyte disturbances, dehydration, undiagnosed stomach pain, congestive heart failure, diabetics and in the elderly.

Patients with impaired gag reflex; who are semi-conscious; who are prone to regurgitation or aspiration; and particularly those with nasogastric intubation; should be carefully observed during the administration of Glycoprep-C®.

Patients with congestive heart failure; pre-existing electrolyte disturbances; kidney disease or impaired renal function; using calcium channel blockers; diuretics or other medications which may affect electrolyte levels may need to be monitored.

There have also been reports of skin reactions and rhinorrhea attributed to macrogol which is contained in Glycoprep-C®.

Glycoprep-C® may cause bloating, distension or abdominal pain, especially if administered by nasogastric tube. If this develops, the rate of administration should be slowed or temporarily ceased until the symptoms abate.

Use in the elderly

Caution should be exercised in the elderly as dehydration and electrolyte depletion may occur. Elderly patients must receive adequate fluids during administration.

Paediatric use

The safety and efficacy in children has not been established.

Effects on laboratory tests

No data available.

4.5 Interaction with other medicines and other forms of interactions

Oral medication taken within one hour of the commencement of the administration of Glycoprep-C®, to one hour after completing its administration, may be flushed from the gastrointestinal tract and not absorbed.

Sustained release preparations, or medicines with a short half-life or a narrow therapeutic window may need to be taken more than one hour before or after administration of Glycoprep-C®.

The low-dose contraceptive pill will not work when taken with Glycoprep-C® as it needs as much time as possible in the gastrointestinal tract for absorption.

There is a possible reduction in the effect of bacitracin and benzylpenicillin when used in conjunction due to the macrogol content of Glycoprep-C®.

4.6 Fertility, pregnancy and lactation

Effects on fertility

No data available.

NEW ZEALAND DATA SHEET

Use in pregnancy (Category - none)

It is not known whether Glycoprep-C® can cause foetal harm or affect reproductive capacity. Glycoprep-C® should only be used if clearly needed.

Use in lactation

No data available.

4.7 Effects on ability to drive and use machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Undesirable effects

Nausea, abdominal fullness and bloating are the most common reactions.

Abdominal cramps, vomiting and anal irritation occur less frequently.

These adverse reactions are usually transient and subside rapidly.

Reporting suspected adverse effects

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

In the event of overdosage, dehydration may ensue. Calcium, potassium, chloride and sodium levels should be carefully monitored and immediate corrective action should be taken to restore electrolyte balance with appropriate fluid replacements.

For advice on the management of overdose, please contact the National Poisons Centre on 0800 POISON (0800 764 766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Alimentary Tract and Metabolism, Drugs for Constipation, Osmotically acting laxatives

ATC code: A06AD65

Mechanism of action

Macrogol 3350 is not significantly absorbed and acts as an osmotic agent to induce a watery diarrhoea usually within 1 hour after commencing treatment and which normally removes the bowel contents by about 4 hours after commencing treatment.

The water and included electrolytes are iso-osmotic with normal intestinal contents and help to reduce or prevent electrolytes or water loss.

Clinical trials

No data available.

5.2 Pharmacokinetic properties

No data available.

5.3 Preclinical safety data

Genotoxicity

No studies have been performed.

Carcinogenicity

No studies have been performed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ascorbic acid 85.16 mg/g

Aspartame 5.11 mg/g

Citric acid 12.77 mg/g

Lemon flavour QL58817 12.77 mg/g

6.2 Incompatibilities

Refer to section 4.2 Dose and method of administration.

6.3 Shelf life

Approved Shelf Life as packaged for sale

2 years

6.4 Special precautions for storage

Store at or below 25°C.

6.5 Nature and contents of container

Sachet (aluminium foil) containing 70 g or 210 g of dry powder

Pack sizes

Sachet 70 g

Sachet 210 g

6.6 Special precautions for disposal

No special requirements for disposal. Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

Restricted Medicine

8 SPONSOR

Fresenius Kabi New Zealand Limited

60 Pavilion Drive

Airport Oaks, Auckland 2022

New Zealand

Freecall: 0800 144 892

NEW ZEALAND DATA SHEET

9 DATE OF FIRST APPROVAL

07 June 1996

10 DATE OF REVISION OF THE TEXT

25 June 2019

SUMMARY TABLE OF CHANGES

| Section Changed | Summary of new information |
|-----------------|---|
| All | Reformat PI as per new Medsafe template |